自身免疫性肝炎患者的SARS-CoV-2感染
该研究合并3个国际登记处数据,比较70例自身免疫性肝炎(AIH)与932例其他病因慢性肝病(非AIH CLD)及769例无肝病患者感染SARS-CoV-2后的结局。AIH患者主要不良结局(住院、ICU、死亡)与非AIH CLD无差异,免疫抑制治疗未增加死亡风险;倾向评分匹配后AIH较无肝病者住院风险增加,但死亡风险相当。
要点
- AIH患者与非AIH慢性肝病者感染SARS-CoV-2后住院、ICU及死亡风险无显著差异。
- AIH队列中死亡相关因素为年龄和肝硬化Child-Pugh B/C级,而非免疫抑制治疗。
- 匹配分析显示AIH患者较无肝病者住院风险增加,但死亡风险无差异。
核心结论
- AIH患者感染SARS-CoV-2后不良结局风险并未高于其他病因慢性肝病及匹配的无肝病人群,尽管多数患者使用免疫抑制治疗。
研究设计与样本
- 研究合并3个国际登记处数据,纳入2020年3月25日至10月24日期间932例慢性肝病合并SARS-CoV-2感染患者,其中AIH 70例。
- 比较AIH与非AIH慢性肝病及无肝病患者的结局,并采用倾向评分匹配分析。
主要发现
- AIH与非AIH慢性肝病主要结局无差异:住院76% vs. 85%(p=0.06),ICU 29% vs. 23%(p=0.240),死亡23% vs. 20%(p=0.643)。
- AIH队列中死亡相关因素包括年龄(OR 2.16/10年;1.07-3.81)和肝硬化Child-Pugh B级(OR 42.48;4.40-409.53)及C级(OR 69.30;2.83-1694.50),免疫抑制使用无关。
- 匹配分析显示AIH与非AIH慢性肝病相比死亡风险差+3.2%(-9.2%-15.7%)。
- 匹配分析显示AIH与无肝病者相比住院风险差+18.4%(5.6-31.2%),死亡风险差+3.2%(-9.1%-15.6%)。
临床怎么用
- AIH患者感染SARS-CoV-2后不应因免疫抑制治疗而过度担忧不良结局,但需关注年龄及肝硬化分期。
- 肝硬化Child-Pugh B/C级的AIH患者感染后死亡风险显著增高,应加强监测。
局限性
- 数据来源于登记处,可能存在报告偏倚和未测混杂因素。
- AIH样本量较小(70例),部分亚组分析效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) continues to have a devastating impact across the globe. However, little is known about the disease course in patients with autoimmune hepatitis (AIH). METHODS: Data for patients with AIH and SARS-CoV-2 infection were combined from 3 international reporting registries and outcomes were compared to those in patients with chronic liver disease of other aetiology (non-AIH CLD) and to patients without liver disease (non-CLD). RESULTS: Between 25th March and 24th October 2020, data were collected for 932 patients with CLD and SARS-CoV-2 infection including 70 with autoimmune hepatitis (AIH). Fifty-eight (83%) patients with AIH were taking ≥1 immunosuppressive drug. There were no differences in rates of major outcomes between patients with AIH and non-AIH CLD, including hospitalization (76% vs. 85%; p = 0.06), intensive care unit admission (29% vs. 23%; p = 0.240), and death (23% vs. 20%; p = 0.643). Factors associated with death within the AIH cohort included age (odds ratio [OR] 2.16/10 years; 1.07-3.81), and Child-Pugh class B (OR 42.48; 4.40-409.53), and C (OR 69.30; 2.83-1694.50) cirrhosis, but not use of immunosuppression. Propensity score matched (PSM) analysis comparing patients with AIH with non-AIH CLD demonstrated no increased risk of adverse outcomes including death (+3.2%; -9.2%-15.7%). PSM analysis of patients with AIH vs. non-CLD (n = 769) demonstrated increased risk of hospitalization with AIH (+18.4%; 5.6-31.2%), but equivalent risk of all other outcomes including death (+3.2%; -9.1%-15.6%). CONCLUSION: Patients with AIH were not at increased risk of adverse outcomes despite immunosuppressive treatment compared to other causes of CLD and to matched cases without liver disease. LAY SUMMARY: Little is known about the outcomes of COVID-19 in patients with autoimmune hepatitis (AIH), a rare chronic inflammatory liver disease. This study combines data from 3 large registries to describe the course of COVID-19 in this patient group. We show that AIH patients do not appear to have an increased risk of death from COVID-19 compared to patients with other forms of liver disease and compared to patients without liver disease, despite the use of medications which suppress the immune system.
引用
- Marjot T, Buescher G, Sebode M, et al. SARS-CoV-2 infection in patients with autoimmune hepatitis. J Hepatol. 2021. PMID: 33508378. doi:10.1016/j.jhep.2021.01.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。